Y.A. Al-Soud et al. / IL FARMACO 59 (2004) 775–783
783
[14] F.B. de Brito, J.E. Sounss, P.J. Warne, Type phosphodiesterase inhibi-
tors and their potential in the treatment of inflammatory diseases,
Emerg. Drugs 2 (1997) 249–268; Chem. Abstr. 127 (1997) 12795s.
[15] M.A. Giembycz, G. Dent, J.E. Sounss, Review: theophyline and
isoenzyme-selective phosphodiestrase inhibitors, Allerg. Allerg. Dis.
1 (1997) 531–567; Chem. Abstr. 127 (1997) 75418s.
[16] R.S. Goldsmith, Review of Medical Pharmacology, fifth ed1974, pp.
634.
[17] G. Sathi, I.P.V.R. Gujrati, C. Nath, J.C. Agrawal, K.P. Bhargava,
K. Shanker, Synthesis and pharmacological evaluation of new ethyl
esters of N-acylamino acids as CNS agents, Pharmazie 315 (1982)
603–609.
[18] C. Dufour, Monoamine oxidase inhibitory theophyllineacethy-
drazides, Fr, Chem. Abstr. 71 (1968) 1,548,987 1969, 81426j.
[19] I. Mir, M.T. Siddiqui, A.M. Comrie, Antituberculosis agents. Part II
a-[5-(2-furyl)-1,3,4-oxadiazol-2-yl-thio)acetohydrazide and related
compounds, J. Chem. Soc. C (1971) 2798–2799.
[20] X. Qian, R. Zhang, Syntheses and insecticidal activities of novel
2,5-disubstituted 1,3,4-oxadiazoles, J. Chem. Tech. Biotechnol. 67
(1996) 124–130.
[21] R. Zhang, X. Qian, Synthesis and bioactivity of 2,5-disubstituted-
1,3,4-oxadiazoles and their N,N′-diacylhydrazine precursors, Yingy-
ong Huaxue 13 (1996) 5–9; Chem. Abstr. 126 (1997) 47158t.
[22] a. R. Zhang, X. Qian, Z. Li, Z., Synthesis and characterization of
2-amino-5-aryl-1,3,4-oxadiazoles containing trifluoroethoxy group,
Flourine Chem. 93 (1999) 39–43
[31] Y.A.Al-Soud, N.A.Al-Masoudi, I.M. Lagoja, Synthesis and reactions
of 1,5- and 1,3-dialkyl derivatives of (D-manno-pentitol-1-yl)-1H-
1,2,4-triazole nucleosides derived from 1-(chloroalkyl)-1-aza-2-
azoniaallene salts, Carbohydr. Res. 318 (1999) 67–74.
[32] Y.A. Al-Soud, N.A. Al-Masoudi, Synthesis and antitumor activity of
some new phthalimide analogues, Pharmazie 56 (2001) 372–375.
[33] Y.A. Al-Soud, R.F. Halah, N.A. Al-Masoudi, Synthesis of 1-[4-(1,5-
disubstituted-1H-1,2,4-triazol-3-yl)benzyl]-1H-indoles and 5,6-
dihaloquinolones as potential antitumor agents, Org. Prep. Proced.
Int. (OPPI) 34 (2002) 648–664.
[34] Y.A. Al-Soud, N.A. Al-Masoudi, A.E.-R.S. Ferwanah, New potential
antitumor agents: 1,2,4-triazoles bearing benzotriazoles, acetoxyhy-
drazides, 5-mercapto-1,2,4-triazoles and sugar hydrazone analogues,
Bioorg. Med. Chem. 11 (2003) 1701–1708.
[35] Y.A. Al-Soud, N.A. Al-Masoudi, Synthesis of 3′-1,2,4-triazolo- and
3′-1,3,4-thiadia-zoliminothymidines, Heteroatom. Chem. 14 (2003)
298–303.
[36] Y.A. Al-Soud, N.A. Al-Masoudi, DNA-directed alkylating agents:
synthesis, antitumor activity and DNA affinity of bis-N,N′-
trisubstituted 1,2,4-triazolo-piprazines, Farmaco 59 (2004) 41–46.
[37] Q. Wang, J.C. Jochims, S. Köhlbrandt, L. Dahlenburg, M. Al-Talib,
A. Hamed, A.E. Ismail, 1,2,4-Triazolium salts from the reaction of
1-aza-2-azoniaallene salts with nitriles, Synthesis (1992) 710–718.
[38] Q. Wang, M. Al-Talib, J.C. Jochims, On the reaction of 1-aza-2-
azoniaallene salts with acetylenes, Chem. Ber. 127 (1994) 541–547.
[39] J.R. Reid, N.D. Heindel, Improved synthesis of 5-substituted-4-
amino-3-mercapto-4H-1,2,4-triazoles, J. Heterocycl. Chem. 13
(1976) 925–926.
[40] W. Willker, D. Leibfritz, R. Kerssebaum, W. Bermel, Gradient selec-
tion in inverse heteronuclear correlation spectroscopy, Mag. Reson.
Chem. 31 (1993) 287–292 and reference therein.
[41] M.F. Summers, L.G. Marzilli, A. Bax, Complete 1H & 13C assign-
ments of coenzyme B12 through the use of new two-dimensional
NMR experiments, J. Am. Chem. Soc. 108 (1986) 4285–4294.
[42] A.L. Davis, J. Keeler, E.D. Laue, D.J. Moskau, Experiments for
recording pure-absorption heteronuclear correlation spectra using
pulsed field gradients, Magn. Reson. 98 (1992) 207–216.
[43] a. J.T. Witkowski, R.K. Robins, R.W. Sidwell, L.N. Simon, Design,
synthesis and broad spectrum antiviral activity of 1-b-D-
ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides,
J. Med. Chem. 15 (1972) 1150–1154
b. R.A. Smith, V. Knight, J.A.D. Smith, Clinical Applications of
Ribavirin, Academic Press, New York, 1994.
[44] P.M. Keller, J.A. Fyfe, L. Beauchamp, C.M. Lubbers, P.A. Furman,
H.J. Schaeffer, G.B. Elion, Enzymetic phosphorylation of acyclic
nucleoside analoges and correlation with antiherpetic activities, Bio-
chem. Parmacol. 30 (1981) 3071–3077 30.
[45] E.D. Reines, P.A. Gross, Antiviral Agents Med. Clin. North Am 72
(1988) 691.
[46] L.M. Beauchamp, B.L. Serling, J.E. Kelsey, J.E. Biron, P. Collins,
J. Selway, J.-C. Lin, H.J. Schaeffer, Effect of acyclic pyrimidines
related to 9-[(1,3-dihydroxy-2-propoxy) methyl]guanines on herpes
viruses, J. Med. Chem 31 (1988) 144–149.
[47] E. De Clercq, P.F. Torrence, Nucleoside analogs with selective antivi-
ral activity, J. Carbohydr. Nucleos. Nucleot. 5 (1978) 187–224.
[48] A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D.Vistica,
C. Hose, J. Langely, P. Cronsie, A. Vaigro-Wolff, M. Gray-Goodrich,
H. Campell, J. Mayo, M.R. Boyd, Feasibility of a high-flux anticancer
drug screen using a divers panel of cultured human tumor cell lines, J.
Natl. Cancer Inst. 83 (1991) 757–766.
b. G. Sahin, E. Palaska, M. Ekizog˘lu, M. Özalp, Farmaco 57 (2002)
539–542.
[23] a. J. Hill, J. R.C. Storr (Ed.), The Comprehensive Heterocyclic Chem
II., Pergamon, Elsevier Science Ltd, Oxford, 1996, pp. 285, For
biological activity of 1,3,4-oxadiazoles, see (chapter 4.06)
b. For biological activity of 1,2,4-triazoles, see: p 162, 163 (chapter
4.02).
[24] J.A. Bush, B.H. Long, J.J. Catino, W.T. Bradner, K. Tomita, Produc-
tion and biological activity of Rebeccamycin, a novel antitumor agent,
J. Antibiotics 40 (1987) 668–678 and references therein.
[25] H. Mujagic, S.-S. Chen, R. Geist, S.J. Occhipinti, B.M. Conger,
C.A. Smith, W.H. Schuette, S.E. Schackney, Effects of Vincristine on
cell survival, cell cycle progression, and miotic accumulation in asyn-
chronously growing Sarcoma 180 cells, Cancer Res. 43 (1983) 3591–
3597.
[26] D.L. Romero, R.A. Olmsted, T.J. Poel, R.A. Morge, C. Biles,
B.J. Keiser, L.A. Kopta, J.M. Friis, J.D. Hosley, K.J. Stefanski,
D.G. Wishka, D.B. Evans, J. Morris, R.G. Stehle, S.K. Sharma,
Y. Yagi, R.L. Voorman, W.J. Adams, W.G. Tarpley, Targeting
Delaviridine/Ateviridine resistance HIV-1, 2: Identification of
(alkylamino)piperidine-containing bis(heteroaryl)piperazines as
broad spectrum reverse trascriptase inhibitors, J. Med. Chem. 39
(1996) 3769–3789.
[27] N.A. Al-Masoudi, N.A. Hassan, Y.A. Al-Soud, P. Schmidt, A.E.-
D.M. Gaafer, M. Weng, S. Marino, A. Schoch, A. Amer, J.C. Jochims,
Synthesis of C- and N-nucleosides from 1-aza-2-azoniaellene and
1,3-diaza-2-azoniaaallene salts, J. Chem. Soc. Perkin Trans. 1 (1998)
947–953.
[28] Y.A. Al-Soud, W.A. Al-Masoudi, R.A. El-Halawa, N.A. Al-Masoudi,
A. N., Synthesis and antiviral activity of some 1,2,4-triazole
C-nucleosides from 1-(chloroalkyl)-1-aza-2-azoniaallene salts,
Nucleos. Nucleot. 18 (1999) 1985–1994.
[29] N.A. Al-Masoudi, Y.A. Al-Soud, A. Geyer, Synthesis and spectro-
scopic analysis some acyclic C-nucleosides and the homo-C-
analogues from 1-(chloroalkyl)-1-aza-2-azoniaallene salts, Tetrahe-
dron 55 (1999) 751–758.
[49] M.R. Boyd, K.D. Paull, Some practical consideration and application
of the National Cancer Institute in vitro anticancer drug screen, Drug
Devel. Res. 34 (1995) 91–109.
[30] Y.A. Al-Soud, N.A. Al-Masoudi, Synthesis and antiviral activity of
some 1-(1,5-dialkyl-1H-1,2,4-triazol-3-yl)thymidines, Arch. Pharm.
Pharm. Med. Chem. 332 (1999) 143–144.